Thursday, May 6, 2021

Advertising

Home Health News Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers...

Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers – OncLive

The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib (AMG 510) and adagrasib in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting.1,2
The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases…

Click here to view the original article.

- Advertisment -
- Advertisment -

Recently Viewed

You might also like ...

Article feature image
Missing piece in NAB’s result might be its biggest win – The Australian Financial Review
Article feature image
Novel CBD analog alleviates pain in mouse model of chemotherapy-induced peripheral neuropathy – News-Medical.Net